Aqua Bio Technology ASA (ABT.OL)
NOK 6.93
(0.0%)
NOK 6.93
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2021 | -16.56 Million NOK | -11.64% |
| 2020 | -14.84 Million NOK | -16.65% |
| 2019 | -12.72 Million NOK | 26.52% |
| 2018 | -17.31 Million NOK | -28.02% |
| 2017 | -13.52 Million NOK | -167.57% |
| 2016 | 20.01 Million NOK | -11.37% |
| 2015 | 22.58 Million NOK | 194.12% |
| 2014 | 7.67 Million NOK | -16.03% |
| 2013 | 9.14 Million NOK | 8.53% |
| 2012 | 8.42 Million NOK | 204.87% |
| 2011 | -8.03 Million NOK | 22.49% |
| 2010 | -10.36 Million NOK | -63.77% |
| 2009 | -6.32 Million NOK | -35.28% |
| 2008 | -4.67 Million NOK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2021 FY | - NOK | -11.64% |
| 2020 FY | - NOK | -16.65% |
| 2019 FY | - NOK | 26.52% |
| 2018 FY | - NOK | -28.02% |
| 2017 FY | - NOK | -167.57% |
| 2016 FY | - NOK | -11.37% |
| 2016 Q1 | 6.52 Million NOK | 0.87% |
| 2016 Q2 | 753.56 Thousand NOK | -88.45% |
| 2016 Q3 | 6.94 Million NOK | 821.94% |
| 2016 Q4 | 6.09 Million NOK | -12.3% |
| 2015 FY | - NOK | 194.12% |
| 2015 Q3 | 5.34 Million NOK | 5.85% |
| 2015 Q4 | 6.46 Million NOK | 21.02% |
| 2015 Q1 | 5.71 Million NOK | 119.33% |
| 2015 Q2 | 5.05 Million NOK | -11.66% |
| 2014 Q3 | 3.84 Million NOK | 10425.09% |
| 2014 Q1 | 1.19 Million NOK | 819.02% |
| 2014 Q2 | 36.49 Thousand NOK | -96.94% |
| 2014 FY | - NOK | -16.03% |
| 2014 Q4 | 2.6 Million NOK | -32.15% |
| 2013 FY | - NOK | 8.53% |
| 2013 Q4 | -166.02 Thousand NOK | -107.71% |
| 2013 Q3 | 2.15 Million NOK | -30.63% |
| 2013 Q2 | 3.1 Million NOK | -23.43% |
| 2013 Q1 | 4.05 Million NOK | 535.25% |
| 2012 Q1 | 9.55 Million NOK | 390.09% |
| 2012 FY | - NOK | 204.87% |
| 2012 Q4 | 638.06 Thousand NOK | -37.61% |
| 2012 Q3 | 1.02 Million NOK | 136.71% |
| 2012 Q2 | -2.78 Million NOK | -129.17% |
| 2011 Q1 | -1.86 Million NOK | 46.46% |
| 2011 Q4 | -3.29 Million NOK | -420.75% |
| 2011 FY | - NOK | 22.49% |
| 2011 Q3 | -632.2 Thousand NOK | 71.83% |
| 2011 Q2 | -2.24 Million NOK | -20.34% |
| 2010 Q2 | -3.6 Million NOK | -96.67% |
| 2010 FY | - NOK | -63.77% |
| 2010 Q4 | -3.48 Million NOK | -95.8% |
| 2010 Q1 | -1.83 Million NOK | 0.0% |
| 2010 Q3 | -1.77 Million NOK | 50.62% |
| 2009 FY | - NOK | -35.28% |
| 2008 FY | - NOK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Arctic Bioscience AS | -37.78 Million NOK | 56.153% |
| ArcticZymes Technologies ASA | 31.64 Million NOK | 152.356% |
| BerGenBio ASA | -191.8 Million NOK | 91.362% |
| Hofseth BioCare ASA | -70.6 Million NOK | 76.534% |
| PCI Biotech Holding ASA | -22.22 Million NOK | 25.446% |
| Thor Medical ASA | -6.82 Million NOK | -142.604% |
| Ultimovacs ASA | -214.85 Million NOK | 92.289% |